AZTherapies commences Ph III Alzheimer's trial; GE researching gene editing;

> AZTherapies is kicking off a Phase III study of its Alzheimer's candidate, a novel formulation of two drugs approved for other indications featuring targeted delivery specific to the disease. Release

> GE is shedding its financial business to focus on its industrial segments, as well as the life sciences. The company's Dharmacon unit has a keen interest in gene editing, known as CRISPR. "We can manipulate genes quite precisely now. The easy part is to switch proteins on and off; an even more interesting application of CRISPR-Cas9 is to change protein expression in order to create, for example, complex synthetic gene circuits," said Anja Smith, Dharmacon's director of research and development. More

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.